[Form 4] Cardiff Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cardiff Oncology director James O. Armitage received a new stock option grant on June 26, 2025. The derivative securities transaction details include:

• Granted 40,565 stock options to purchase common stock
• Exercise price set at $3.16 per share
• Options become exercisable on June 26, 2026
• Options expire on June 26, 2035
• Following this grant, Armitage now beneficially owns 187,539 derivative securities directly

This Form 4 filing represents a standard director compensation stock option grant, which vests one year from the grant date and has a 10-year exercise period. The transaction appears to be part of the company's regular director compensation program rather than an open market transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Armitage James O

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3.16	06/26/2025		A		40,565		06/26/2026	06/26/2035	Common Stock	40,565	$0	187,539	D

Explanation of Responses:

	/s/ James Armitage	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did CRDF director James Armitage receive on June 26, 2025?

According to the Form 4 filing, CRDF director James Armitage received 40,565 stock options on June 26, 2025, with an exercise price of $3.16 per share.

What is the expiration date for James Armitage's new CRDF stock options?

The stock options granted to James Armitage on June 26, 2025, have an expiration date of June 26, 2035, giving them a 10-year term from the grant date.

How many total stock options does James Armitage own in CRDF after this grant?

Following this transaction, James Armitage beneficially owns 187,539 stock options in Cardiff Oncology (CRDF), held in direct ownership form.

What is the exercise price of CRDF stock options granted to James Armitage in June 2025?

The stock options were granted with an exercise price of $3.16 per share.

When do James Armitage's new CRDF stock options become exercisable?

According to the Form 4 filing, the stock options become exercisable on June 26, 2026, one year after the grant date.